title: An Economic Model to Compare the Different Empiric and First/Second Line Treatment Regimens for Suspected Methicillin-Resistant Staphylococcus Aureus Nosocomial Pneumonia.
authors.affiliation: Pharmerit North America LLC, Bethesda, MD, USA.
authors.forename: D
authors.initials: D
authors.lastname: Patel
authors.affiliation: Winthrop-University Hospital, Mineola, NY, USA.
authors.forename: M S
authors.initials: MS
authors.lastname: Niederman
authors.affiliation: Pfizer, Inc., San Diego, CA, USA.
authors.forename: J Z
authors.initials: JZ
authors.lastname: Li
authors.affiliation: Pfizer Inc, Collegeville, PA, USA.
authors.forename: R
authors.initials: R
authors.lastname: Mcnamara
authors.affiliation: Pfizer Inc, Groton, CT, USA.
authors.forename: S
authors.initials: S
authors.lastname: Haider
authors.affiliation: Pharmerit International, Bethesda, MD, USA.
authors.forename: J
authors.initials: J
authors.lastname: Stephens